Year: 2022

Novaremed_Logo

Novaremed Enters Into an Exclusive Option and License Agreement With NeuroFront for the Non-opioid Neuropathic Pain Treatment, NRD.E1, for Greater China and Singapore

NeuroFront receives an exclusive option for an exclusive license to develop, commercialize and manufacture NRD.E1, Novaremed’s first-in-class, non-opioid investigational drug...

image-1

Technology, Media, and Telecommunications (TMT) and Transport Industry Groups were Singapore’s Top Cyber Targets in 2021: Ensign InfoSecurity Report

Ransomware, multi-modal attacks, and cyber supply chain compromises emerge as key cyber threat trends impacting organisations in 2022 SINGAPORE -...